Show simple item record

Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in Kenya

dc.contributor.authorJaoko Walter G
dc.contributor.authorOGUTU, H.
dc.contributor.authorWAKASIAKA, S.
dc.contributor.authorMALOGO, R.
dc.contributor.authorNDAMBUKI, R.
dc.contributor.authorNYANGE, J.
dc.contributor.authorOMOSA-MANYONYI, G.
dc.contributor.authorFAST, P.
dc.contributor.authorSCHMIDT, C.
dc.contributor.authorVERLINDE, C.
dc.contributor.authorSMITH, C.
dc.contributor.authorBHATT, KM.
dc.contributor.authorNdinya-Achola, JO
dc.contributor.authorANZALA, O.
dc.date.accessioned2013-02-18T07:05:04Z
dc.date.issued2009
dc.identifier.citationEast African Medical Journalen
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/21644413
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10067
dc.description.abstractFemale participants in AIDS candidate vaccine clinical trials must agree to use effective contraception to be enrolled into the studies, and for a specified period after vaccination, since the candidate vaccines’ effects on the embryo or foetus are unknown.country settings. Effective female-controlled contraceptives, administered at the clinical trial site, may empower female participants to better control their fertility, leading to more complete clinical trial data.en
dc.language.isoenen
dc.titlePregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in Kenyaen
dc.typeArticleen


Files in this item

Thumbnail
Name:
abstract.pdf
Size:
6.700Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record